Regulatory Approval Granted for Phase II Clinical Trial of Oral Ebola Treatment in DR Congo

NanoViricides, Inc. has received regulatory approval from ACOREP in the Democratic Republic of Congo (DRC) to initiate a Phase II clinical trial for NV-387 Oral Gummies. This investigational treatment targets the current Bundibugyo Ebolavirus outbreak and other Ebola viruses, representing a significant step in developing new therapies for this severe infectious disease.